Status
Conditions
About
This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.
Full description
Due to the cross-sectional design, participants will only have to visit Leiden University Medical Center (LUMC) once. For patients already treated in the LUMC, we will try to align this visit with a standard clinical appointment.
After inclusion, all baseline data, consisting of demographics, clinical history and a number of questionnaires (four for MG participants, three for non-MG participants), will be collected. The symptom-specific assessments are performed in a standard order, with the most fatiguing task (i.e. proximal arm fatigue static assessment) last. We estimate the visit will take a total of 60 minutes.
This study is considered to be low risk. Withholding pyridostigmine for a limited period is part of standard care of MG (before investigations or clinical assessments) and does not affect long term clinical outcome. MG participants will consent to withhold pyridostigmine for 12 hours prior to the study visit if they are on this treatment and restart it after the visit. As this is a non-interventional, observational study where only questionnaire-based and non-contact digital data are being collected, the only source of marginal risk relates to data protection and confidentiality, including arrangements for the transfer and storage of data. Given it would not be possible to deidentify the digital audio or video data while maintaining the requisite integrity for data analysis, we will seek explicit consent for the sharing of this information in this identifiable format.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion Criteria for MG participants only:
Inclusion Criteria for non-MG participants only
Exclusion criteria
Exclusion Criteria for MG participants only:
Exclusion Criteria for non-MG participants only:
1. Limitation of upper limb mobility or speech impairment of any cause.
225 participants in 2 patient groups
Loading...
Central trial contact
Yvonne JM Campman, MD; Martijn R Tannemaat, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal